CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 100 enrolled
Drug / intervention
IV ondansetron 4 mg q 6 hours for a total of 4 doses +3 moredrug
Likely dose
IV ondansetron 4 mg q 6 hours for a total of 4 dosesfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01510379
NCT01510379N/ACompleted

Median Nerve Acustimulation Plus Medical Anti-emetic Therapy for Control Post-operative Nausea in Patients Undergoing Foregut Surgery: A Randomized Control Trial

Kyle A Perry·interventional·Posted Jan 16, 2012·Updated Mar 5, 2014

In Brief

A clinical study evaluating Reletex, IV ondansetron 4 mg q 6 hours for a total of 4 doses, and 2 other interventions for Nausea and Vomiting Post-foregut Surgery. Completed, enrolled 100 participants across 1 site.

Detailed Summary

The effect a ReletexTM device has on postoperative nausea and vomiting when used with ondansetron after foregut surgery will be studied. A ReletexTM device is a FDA approved wristwatch-like device that painlessly stimulates a nerve in the wrist and has been shown to decrease nausea and vomiting. The investigators will randomize 100 patients who are having a fundoplication for either gastroesophageal reflux disease (GERD), paraesophageal hernia, or Heller Myotomy for achalasia into two groups. A control group will receive scheduled ondansetron for prevention and treatment of postoperative nausea and vomiting and phenergan as needed. The treatment group will wear a ReletexTM wrist band after surgery for 7 days. These patients will also get scheduled ondansetron and phenergan as needed, like the control group. The investigators will compare nausea, retching, and the amount of supplemental nausea medication used between the two groups. The patients will be provided a diary to document their nausea, retching, and medication use. The hypothesis of this study is that use of the ReletexTM device will reduce post-operative nausea and vomiting, and will reduce post-operative use of anti-emetic medications in patients who have undergone foregut surgery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedJan 16, 2012
Enrollment StartAug 1, 2011
Primary CompletionJul 1, 2012
Study CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 14.5 years ago

Interventions

Reletexdevice

Neurostimulation device for prevention/treatment of post-operative nausea and vomiting, Reletex arm.

IV ondansetron 4 mg q 6 hours for a total of 4 dosesdrug

IV promethazine 25 mg q 6 hours prndrug

Elixir promethazine 25 mg q 6 hours prn after dischargedrug